In its simplest form, a refractive surgery consultation is a structured conversation with a patient about their candidacy for surgical intervention. More specifically, there are two interlocking parts of the process: a comprehensive evaluation of the eye and a goal-oriented dialogue about the patient’s visual needs, desires, and expectations. As refractive surgeons, it is our responsibility to approach each consultation not as a transaction, but as the first step in a long-term relationship with a patient’s ocular health, accounting for not only where their eyes are currently but also where they may be decades from now.

The shift away from refractive error as the primary decision variable toward corneal health, axial length, and long-term ocular preservation represents, to me, one of the most meaningful conceptual advances in refractive surgery over the past decade. It changes not only which patients we recommend for surgery, but also how we speak with them, what we promise, and how we set expectations for a lifetime of visual health rather than a single correction event.

Start with the eye, not the prescription

A comprehensive ocular evaluation has two fundamental objectives:

1. assess the eye's overall health, including the ocular surface and tear film, cornea, crystalline lens, and stability of the refractive error over time and

2. evaluate visual quality, including higher-order aberrations, contrast sensitivity, and ocular dominance.

Getting to know about the patient’s life, occupation, and hobbies is also important to understand what they ask of their vision at varying ranges, and in both daytime and nighttime environments.

What is conspicuously absent from the list is a diopter threshold. In our practice, we do not recommend one refractive surgery procedure over another based on prescription alone. Rather, we consider the relationship between keratometry, axial length, and refraction with and without cycloplegia. We measure endothelial cell count, assess corneal biomechanics, and perform both anterior and posterior segment OCT. In other words, we look at the whole eye.

A case for corneal preservation

The most critical measurement for patients with myopia is axial length. For anything greater than 25 mm, implantation of an EVO ICL (STAAR Surgical) is preferred in our clinic regardless of the associated refractive error. We have more than 30 years of follow-up dictating an average axial length progression of at least 0.25 mm for 66% of patients in the following 20 years after surgery. This is roughly equivalent to 0.75 D of myopia.

Posterior staphyloma is another reason to consider axial length rather than diopter value as the primary criterion for Implantable Collamer Lens (ICL). On posterior segment OCT, a macular plane tilt greater than 30º can produce 1 to 2 lines of visual acuity loss and meaningful degradation of contrast sensitivity and night vision. In a patient who already carries this anatomical burden, aggressive corneal reshaping may compound rather than solve the problem. A flat cornea on top of a retinal staphyloma is a formula for dissatisfied patients.

When properly conceived, refractive surgery is a longitudinal strategy instead of a one-time transaction. However, corneal ablation is not without consequence. Removing tissue from a cornea that is already biomechanically stressed forecloses options that may be desirable later. That loss is rarely apparent at the time of the original surgery. By contrast, a patient who receives an ICL in their 30s preserves a cornea for laser enhancement if myopia progresses or for a presbyopia-correcting IOL when they later develop a cataract. Protecting corneal tissue now, in many ways, protects the patient’s visual future.

Guiding patients through the procedural conversation

By the time I sit down to discuss surgical options with a patient, the refractive evaluation has usually already answered the central question. I have a clear picture of which procedure best fits their eye, and my role in the consultation shifts from assessment to communication.

Patients care about the quality of their vision, the safety of the intervention, and their long-term outcomes. When a recommendation is explained thoroughly and honestly, most patients are receptive, even when the procedure differs from what they expected walking in. The following reflects our preferred decision framework.

Healthy cornea, normal biomechanics, and axial length under 25 mm. LASIK, PRK, and SMILE are all appropriate options provided the refractive error falls comfortably within the predictable range for laser vision correction. In these cases, the final choice may legitimately incorporate the patient's preferences for recovery time, lifestyle demands, and tolerance for dry eye risk.

Axial length exceeding 25 mm or any concern about corneal biomechanical reserve. EVO ICL is presented as the primary recommendation for the reasons discussed previously: corneal preservation, protection against myopia progression, and safeguarding future surgical options.

Hyperopia. Corneal ablation for high hyperopic corrections carries increased visual quality penalties compared to ICL, including greater induction of higher-order aberrations and long-term refractive regression (1, 2).For this reason, anterior chamber depth (ACD) is the primary criterion guiding our recommendation. Anything greater than 3 mm is an indication for ICL regardless of the magnitude of hyperopia. In select cases, ICL may be considered for an eye with an ACD of 2.8 mm following specific informed consent. The principle is consistent: the measurement drives the decision, not the prescription.

Astigmatism. We have a saying in our practice: astigmatism is a bad travel companion. It is addressed on the cornea whenever possible. Two possible solutions are limbal relaxing incisions in combination with ICL and a bioptics procedure paired with the ICL. Toric ICLs are available and effective, but our preference is to correct cylinder at the cornea and reserve a phakic IOL for spherical correction.

Quality-of-life outcomes

The goal of refractive surgery extends beyond eliminating glasses and/or contact lenses. The right procedure should give a patient the greatest possible functional freedom across the whole arc of their visual life. For patients between the ages of 45 and 55, this consideration leads us to favor ICL over refractive lensectomy when the anatomy supports it. Removing a healthy crystalline lens carries retinal risks, particularly in eyes with long axial lengths (3). EVO Viva ICL, designed specifically for this population, is an important advance in this direction.

I also try to be honest with patients about what surgery cannot guarantee. A patient with an axial length of 27 mm and a posterior staphyloma may have excellent functional vision after ICL implantation, but they carry an elevated risk of myopic macular degeneration, glaucoma, and retinal pathology that no refractive procedure changes (4). Understanding that myopia is a disease rather than a refractive inconvenience helps shape the entire conversation, elevating what we are doing from cosmetic surgery to meaningful clinical intervention.

Clinical and strategic implications

Surgeons who embrace a broader framework for refractive surgery planning may find that it expands their refractive practice in ways that purely diopter-based thinking does not. There is a substantial population of patients with axial lengths between 25 and 26 mm whose myopia may be anywhere from -2.00 to -10.00 D. Under traditional criteria, many of these patients might never be referred for ICL consultation or might self-select for laser vision correction based on a cursory review of their prescription. An axial-length–guided approach captures these patients and gives them a more diverse pool of options.

The same logic applies at the other end of the refractive spectrum. A patient with low hyperopia and a deep anterior chamber who wants spectacle independence is not automatically best served by surface ablation. When we evaluate them on the full biometric picture, an ICL may deliver superior optical quality and long-term stability.

To me - and for surgeons building or refining a refractive program - these conversations are worth having. A practical first step is evaluating your diagnostic infrastructure. Corneal tomography, anterior and posterior segment OCT, axial length measurement, corneal biomechanics assessment, and endothelial cell count should be routine components of the evaluation. This also encompasses cultivating the intellectual habit of reviewing all results before thinking about refractive error.

The second step is conceptual. We are long overdue for a reframing of refractive surgery education. The traditional divisions of corneal and lens-based surgery should give way to a unified concept of surgery, with therapeutic and refractive objectives applied in sequence or combination as an individual patient requires. When we are able to achieve this, we are better positioned to treat the cornea and lens as a functional unit across the full timeline of a patient's visual life.

Conclusion

Refractive surgery has achieved extraordinary levels of safety, predictability, and efficacy. The next step is to deploy all the tools we have at our disposal with the wisdom that comes from thinking beyond the prescription and seeing the patient in front of us as a whole eye, a full life, and a long future. In my experience, those patients who see their surgeon thinking about their cornea at age 60, not just their acuity at age 35, tend to be more trusting, engaged, and satisfied with their outcomes.